Meal-induced increases in C-reactive protein, interleukin-6 and tumour necrosis factor α are attenuated by prandial + basal insulin in patients with Type 2 diabetes
Diabet. Med. 28, 1088–1095 (2011) Aim To determine if a regimen with prandial + basal insulin compared with basal insulin attenuates post‐meal inflammatory and glycative biomarkers in patients with Type 2 diabetes. Methods This test‐meal sub‐study in the USA is from a previously reported clinical...
Saved in:
Published in: | Diabetic medicine Vol. 28; no. 9; pp. 1088 - 1095 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Oxford, UK
Blackwell Publishing Ltd
01-09-2011
Blackwell |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Diabet. Med. 28, 1088–1095 (2011)
Aim To determine if a regimen with prandial + basal insulin compared with basal insulin attenuates post‐meal inflammatory and glycative biomarkers in patients with Type 2 diabetes.
Methods This test‐meal sub‐study in the USA is from a previously reported clinical trial comparing the effect on glycaemic control of 24 weeks of thrice‐daily pre‐meal insulin lispro mix 50 (50% insulin lispro, 50% insulin lispro protamine suspension) or bedtime insulin glargine, both plus metformin. In the sub‐study, glucose, insulin, triglycerides, high‐sensitivity C‐reactive protein, tumour necrosis factor α, interleukin‐6, methylglyoxal and 3‐deoxyglucosone were measured during the post‐meal period of a mixed‐meal breakfast at the final visit. Prandial + basal (n = 25) and basal (n = 21) insulin were administered at the same times as during the previous 24 weeks.
Results Post‐meal, the prandial + basal insulin group had significantly higher insulin, lower glucose and triglycerides, as well as lower high‐sensitivity C‐reactive protein, tumour necrosis factor α and interleukin‐6, than the basal insulin group. Glucose incremental area under the concentration curve significantly correlated with high‐sensitivity C‐reactive protein, tumour necrosis factor α, interleukin‐6, methylglyoxal and 3‐deoxyglucosone incremental area under the concentration curve. Insulin incremental area under the concentration curve correlated inversely with high‐sensitivity C‐reactive protein and tumour necrosis factor α incremental area under the concentration curve. However, after adjusting for glucose incremental area under the concentration curve, these inverse correlations were no longer significant. Triglyceride incremental area under the concentration curve was not correlated with any biomarker incremental area under the concentration curve.
Conclusions Controlling post‐meal hyperglycaemia with prandial + basal insulin in patients with Type 2 diabetes attenuates meal‐induced increases in high‐sensitivity C‐reactive protein, interleukin‐6 and tumour necrosis factor α compared with basal insulin. The rise in post‐meal glucose, but not triglycerides, significantly correlated with the rise in post‐meal inflammatory and glycative biomarkers. |
---|---|
Bibliography: | ark:/67375/WNG-Z1136628-S ArticleID:DME3324 istex:2AE56B26A7849AD76CBE9E64B523F3C27DC36CF1 The present address of H. Yuan is the Canadian Agency for Drugs and Technologies in Health, Ottawa, ON, Canada. The present address of D. C. Robbins is the Department of Medicine, University of Kansas School of Medicine, Kansas City, Kansas, USA. Re‐use of this article is permitted in accordance with the Terms and Conditions set out at The present address of M. H. Tan is the Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI, USA. http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms The present address of S. Sarwat is i3 Statprobe, Indianapolis, IN, USA. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms |
ISSN: | 0742-3071 1464-5491 |
DOI: | 10.1111/j.1464-5491.2011.03324.x |